The MOF rebounded slightly in February. Read more.
READ MOREThe month of February was a strong month for the Merchant Biotech Fund (Fund or MBF) finishing up 16.71%. Read more.
READ MOREWe are starting to see green shoots in our sector of the market of late. Read more.
READ MOREThe Merchant Biotech Fund (MBF or Fund) started the 2024 calendar year well, finishing up 11.12% for the month of January. Read more.
READ MOREClosing out the year the Merchant Biotech Fund finished up strongly. Read more.
READ MOREPleasingly the Merchant Opportunities Fund rebounded somewhat during the month of December. Read more.
READ MOREThe Merchant Biotech Fund (MBF or Fund) had a strong month in November, finishing at $1.0058. Read more.
READ MOREThe bright spot at Merchant has been the performance of the Merchant Biotech Fund. Read more.
READ MOREThe general market softened into September and the biotech sector held its ground. Read more.
READ MOREGreetings from Munich. I am here at the moment assisting HAPA (EuroCann). Read more.
READ MOREAt the end of July, it appeared the Australian inflation rate was softening with monthly CPI hitting a 16-month low. Read more.
READ MOREA quiet month in the markets post June 30th selling in Small-Cap land. Read more.
READ MOREThe Merchant Opportunities Fund softened in the month of June. Read more.
READ MOREThe Merchant Biotech Fund finished up 43.25% for the financial year. Read more.
READ MOREThe Merchant Biotech Fund (“MBF” or “the Fund”) is up 59% for the financial year vs the ASX Healthcare 300 Index (XHK) up 6.09% over the same period. Read more.
READ MOREThe overall market was relatively stagnant during the month of April. Read more.
READ MOREThe Merchant Biotech Fund closed up 5.5% for the month. Read more.
READ MOREMarch was a tale of two halves – first half being terrible and second half being less terrible… Read more.
READ MOREGlobal equities declined in February after a strong January. Merchant Biotech Fund (MBF or Fund) retreated a little to finish the month $0.7691.Read more.
READ MOREThe month of February was a tale of two halves – first half of the month being relatively good and second half being relatively bad as the index wobbled across the board as a result of continued increases in global interest rates. Read more.
READ MOREA solid January could be a good sign for the market and potentially foreshadow a continued uptick in the months that follow. Read more.
READ MOREAnother relatively benign month for the Merchant Opportunities Fund. Read more.
READ MOREThe Merchant Opportunities Fund (MOF) is currently up 19.60% net of fees since 30 June 2022. Read more.
READ MOREThe Merchant Biotech Fund (MBF) finished December up 29.34% for the Financial Year. Read more.
READ MORENovember started on a sombre note amid the Fed’s rate hike and better-than-expected job numbers. Read more.
READ MOREThe ASX continued to tread water in November and settled into the Christmas trading period with a marked drop in liquidity despite an overall bullish trend. Read more.
READ MOREGlobal equity markets rounded the month out higher after a brutal September slump. In the US the Dow ended October with a gain of +13.96%, its best monthly advance since January 1976 and its 10th best month of the last century. Read more.
READ MOREApologies for the lateness of this newsletter, I’ve just returned from Frankfurt where we’ve been visiting HAPA Pharm, our German Medical Cannabis holding as it readies to list in the new year. Read more.
READ MOREThis month the bear market intensified, with the S&P 500 joining the Dow Jones in undercutting their June lows and the Nasdaq composite sitting just above that level. Read more.
READ MOREThe Merchant Opportunities Fund (MOF) had a relatively benign month given the global market swings during September. Read more.
READ MOREThe question we wanted answered in July was “can the rally last?” August provided the answer. Read more.
READ MOREThe Merchant Opportunities Fund (MOF or Fund) pulled back slightly along with the market during the month of August to be up 18.40% for the Financial Year. Read more.
READ MOREAt the closing bell on the last trading day of the Financial Year, the ASX Biotech Sector was down approximately 40% for the full Financial Year. Read more.
READ MOREWell, that was a financial year to forget! Read more.
READ MOREThe MOF is currently down 15.41% since 30 June against a Small Ordinaries Index that is at the time of writing, down 19.94% for the Financial Year. Read more.
READ MOREAgainst the ASX & US Listed Biotech Indexes we are faring better but at the moment it’s all a little painful. Read more.
READ MOREApril brought another volatile month on the stock market. The release of inflation numbers and a rise in interest rates both globally and domestically led to a shakeout. Read more.
READ MOREWith the Small Ordinaries off 15.36% for the 6 months, the Merchant Opportunities Fund (MOF) over for the financial year is currently down 12.18%. Read more.
READ MOREAs the dust settles on the month of March 2022 for the Merchant Biotech Fund increasing inflation and the Russian war in Ukraine continue to plague the technology/healthcare sector. Read more.
READ MOREThe Merchant Opportunities Fund is currently down 6.25% for the Financial Year having regained some ground to March 31st. Read more.
READ MOREThe Merchant Biotech Fund continued to suffer during February with the Biotechnology and Technology sectors both being hardest hit as a result of the Russian invasion of Ukraine.
READ MOREThe Merchant Opportunities Fund continued its retracement at the hands of the market gods in February.
READ MOREAuspiciously January 2022 will go down as the first month investing for the Merchant Biotech Fund.
READ MOREJanuary was a tough month for equity markets. The long-awaited inflation figures officially came into focus.
READ MOREThe overall market continued its soft run into the end of the calendar year with renewed fears of inflation stoking market unrest across all sectors of the market.
READ MOREThe Merchant Opportunities Fund (MOF) was a little choppy during the month of September.
READ MOREThe Merchant Opportunities Fund (MOF or Fund) has started the Financial Year quietly.
READ MOREThe Merchant Opportunities Fund (MOF) finished the 2021 Financial Year up 46.71%.
READ MOREThe month of May was relatively soft for the broader Merchant Opportunities Fund (MOF).
READ MOREThe Merchant Opportunities Fund slipped slightly from its all-time high in March.
READ MORE